Table 1 Baseline characteristics for patients with eGFR values at baseline and month 12
High ferritin FCM (n = 97) | Low ferritin FCM (n = 89) | Oral iron (n = 167) | |
|---|---|---|---|
Age, years | 69.3 (12.9) | 69.0 (12.1) | 69.6 (12.7) |
Female gender, n (%) | 61 ((62.9) | 56 (62.9) | 106 (63.5) |
White race, n (%) | 93 (95.9) | 83 (93.3) | 159 (95.2) |
Body mass index, kg/m2 | 30.5 (6.8) | 30.0 (5.3) | 29.4 (5.4) |
History of diabetes, n (%) | 61 (62.9) | 59 (66.3) | 106 (63.5) |
Endogenous erythropoietin, mIU/mL | 29.4 (24.6) | 29.6 (27.4) | 26.3 (20.9) |
Hb, g/dL | 10.4 (0.7) | 10.5 (0.9) | 10.7 (0.6) |
Ferritin, μg/L | 54.2 94.9) | 45.8 (44.3) | 52.4 (39.9) |
TSAT, % | 16.3 (20.2) | 14.9 (7.5) | 14.8 (7.0) |
C-reactive protein, mg/L | 7.4 (13.4) | 5.7 (5.9) | 5.3 (6.5) |
ACE inhibitor therapy prior to study entry, n (%)a | 32 (33.0) | 37 (41.6) | 69 (41.3) |
Angiotensin II antagonist therapy prior to study entry, n (%)b | 41 (42.3) | 33 (37.1) | 77 (46.1) |